A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to determine if a supplement of an omega-3-fatty acid (docosahexaenoic - DHA) lowers inflammation in human fat tissue thereby lowering estrogen production and the potential risk for breast, rectal and colon cancers. The investigators also aim to study how this occurs to discover the basis for other potential treatments to lower estrogen production in fat tissue and decrease the risk of breast cancer. Additionally, this study will evaluate the effectiveness of DHA supplements in reducing inflammation and the risk for colon cancer.
| Condition | Intervention |
|---|---|
|
Breast Cancer Rectal Cancer Colon Cancer Obesity |
Dietary Supplement: dietary intervention |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study |
- Reduced subcutaneous fat [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]Reduced subcutaneous fat and colorectal mucosal inflammation changes between pre and post treatment as seen by histologic quantification of monocyte aggregations (crowns), CD68 and CD163 stained macrophages in fat biopsies, as well as, mediators of mucosal inflammatory and immune protein concentrations in rectosigmoid biopsies.
- multiplex bead assay/immunoassay [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Lowered aromatase expression in fat biopsies accompanied by decreases in the synthetic enzyme COX1-MPGES-1 and/or increase in the catabolic enzyme 15-PGDH and associated changes in BRAC-1 and SIRT-1 expression.
by immunohistochemical evaluation of CD68, CD168 and CD3 stained monocytes and through examination of the mRNA of imune inflammatory markers.
Alteration in serum estradiol and testosterone levels and/or changes in circulating cytokines/chemokines measured by multiplex bead assay and immuoassay.
| Estimated Enrollment: | 17 |
| Study Start Date: | May 2010 |
| Study Completion Date: | April 2013 |
| Primary Completion Date: | April 2013 (Final data collection date for primary outcome measure) |
-
Dietary Supplement: dietary intervention
Breast cancer and colorectal cancer are two of the most frequently seen cancers in the United States. Breast cancer occurs at all ages but is particularly common in post menopausal women. Obesity increases the risk of breast cancer primarily of the type that is stimulated by the female sex hormone estrogen. In obesity, fat cells produce estrogen which can alter breast tissue, while lowering blood estrogen reduces the incidence of breast cancer. Inflammation of fat tissue, the coronary blood vessels and the liver are also seen with obesity. Animal experiments have shown the inflammation in fat tissue increases the production of estrogen, thus reducing inflammation in fat tissue might lower estrogen levels and the risk of breast cancer in obese women. Obesity simultaneously increases the inflammation of colon tissue. Since chronic inflammation in the colon is a co-factor in rectal and colon cancers, reducing inflammation should lower the risk of developing these cancers as well. A diet high in omega-3-fatty acids, such as those found in fish oil, has been shown in mice to reduce inflammation and aromatase expression (rate limiting enzyme for estrogen synthesis) in fat tissue and to reduce inflammation in the colon of mice and humans.
This pilot study of five obese, postmenopausal women will include nutritional and medical evaluations, a four day inpatient hospital stay on a regular diet, and to measure the inflammation and the estrogen producing machinery and resting energy of each volunteer subject, as well as, biopsies of abdominal fat tissue and the inflammation in the sigmoid colon obtained by sigmoidoscopy. Following these baseline measurements, subjects will be provided DHA supplements to take daily for three months and requested to weigh themselves twice weekly at home with the goal of maintaining their weight. Telephone interviews will be performed at scheduled points to check-in with the subjects and after six weeks blood tests will be performed. At three months each subject will be readmitted to the hospital and repeat the tests performed before starting on the DHA supplement. If the study shows feasibility and positive results it will be extended to more subjects and other interventions in the future.
Eligibility| Ages Eligible for Study: | 40 Years to 70 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Post-menopausal defined as:
- 24 consecutive months without a menstrual period AND
- low serum estradiol level (<40 ng/ml) to be assessed at screening AND
- not taking any medication known to induce ammenorhea AND
- no known endocrine abnormality associated with irregular/absent menses.
- BMI greater than 35.
Exclusion Criteria:
- Currently taking any hormone therapy: oral, transplanted, vaginal, injected
- Currently taking NSAIDS (if > once a week, stopped < 30 days ago)
- Currently taking oral hypoglycemics
- Currently taking anticoagulants or stopped < 30 days ago
- Any history of a malignancy excluding basal and squamous cell skin cancer
- Blood Pressure > 150/90 at screening
- History of any bleeding disorder
- LFT results > 2x normal upper limits
- Renal lab value results > 2x normal upper limits
- Any condition or situation which, in the investigator's opinion, puts the patient at significant risk, could complicate the study results, or may interfere significantly with participation in the study.
- History of intestinal malabsorption
- RBC's (red blood cells) on screening urinalysis
- History of chronic diarrhea
- Using any drug study medications or multiple medications that might change the bowel lining.
- On any medications that can alter fat stores or large bowel inflammation as deemed by the principal investigator
- History of inflammatory bowel disease
- Abnormal thyroid function based on screening labs
- Currently using any weight control medication
- HIV positive as per POCT rapid test at screening
- Currently taking fish oil, omega-3 supplements or other herbals that exceed the GRAS (Generally Recognized As Safe)
- Fasting blood sugar greater than 126 mg/dL at screening
- Currently taking more than 3 antihypertensive medications
Contacts and Locations| United States, New York | |
| The Rockefeller University | |
| New York, New York, United States, 10065 | |
| Principal Investigator: | Peter Holt, MD | The Rockefeller University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Rockefeller University |
| ClinicalTrials.gov Identifier: | NCT01127867 History of Changes |
| Other Study ID Numbers: | PHO-0702 |
| Study First Received: | May 19, 2010 |
| Last Updated: | May 16, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Breast Neoplasms Colonic Neoplasms Rectal Neoplasms Obesity Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms |
Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013